La Terrasse, France

Xavier Leverve

This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignees: National Institute of Health and Medical Research, Poxel. Active years: 2015.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Xavier Leverve

Introduction

Xavier Leverve is a notable inventor based in La Terrasse, France. He has made significant contributions to the field of medical science, particularly in the treatment of ischemia and reperfusion-related diseases. His innovative work has led to the development of a unique patent that addresses critical health issues.

Latest Patents

Xavier Leverve holds a patent for amino derivatives of dihydro-1,3,5-triazine, which are utilized in the treatment and prevention of diseases induced by ischemia and reperfusion. This invention is particularly relevant for addressing cardiac and renal complications, showcasing his commitment to advancing medical treatments. He has 1 patent to his name.

Career Highlights

Throughout his career, Xavier has worked with reputable organizations, including Poxel and the National Institute of Health and Medical Research. His experience in these institutions has allowed him to refine his expertise and contribute to groundbreaking research in his field.

Collaborations

Xavier has collaborated with esteemed colleagues such as Didier Mesangeau and Daniel Cravo. These partnerships have further enriched his work and expanded the impact of his inventions.

Conclusion

Xavier Leverve's contributions to medical science through his innovative patent demonstrate his dedication to improving health outcomes. His work continues to inspire advancements in the treatment of ischemia and reperfusion-related diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…